Wyeth Sued For Off-Label Rapamune Sales
Wyeth Pharmaceuticals Inc. has been hit with an amended whistleblower complaint alleging that the company illegally marketed Rapamune — a drug used in kidney transplants — for use in other, unapproved...To view the full article, register now.
Already a subscriber? Click here to view full article